

Haematologica
HAEMATOL/2017/172411
Version 3

Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia, results from two clinical trials

Richard Schlenk, Jürgen Krauter, Emmanuel Raffoux, Karl-Anton Kreuzer, Markus Schaich, Lucien Noens, Thomas Pabst, Madhuri Vusirikala, Didier Bouscary, Andrew Spencer, Anna Candoni, Jorge Sierra Gil, Noah Berkowitz, Hans-Jochen Weber, and Oliver Ottmann

Disclosures: Dr. Schlenk reports speaker fees from Novartis. Dr. Oliver Ottmann reports honoraria from Novartis, Sunesis and Pfizer for advisory board participation. Dr. Krauter reports grants from Novartis during the conduct of the study, Dr. Kreuzer reports speaker fees and Honoraria from Novartis. Dr. Sierra reports grants and personal fees from Celgene, personal fees from Pfizer, grants from Amgen, personal fees from Janssen, personal fees from Abbvie, grants and personal fees from Novartis. Dr. Bouscary, Dr. Candoni, Dr. Noens, Dr. Pabst, Dr. Raffoux, Dr. Schaich, Dr. Spencer, and Dr. Vusirikala have nothing to disclose. Dr. Noah Berkowitz and Hans-Jochen Weber are employees of Novartis.

Contributions: All authors, participated in study design, data analysis and drafting of manuscript content. Dr. Noah Berkowitz and Hans-Jochen Weber are employees of Novartis and contributed to both clinical study design and data analysis. Dr. Richard Schlenk, Dr. Jürgen Krauter, Dr. Emmanuel Raffoux, Dr. Markus Schaich, Dr. Didier Bouscary, are principal investigators who contributed the patient data for the panobinostat combination study CLB589B2116 with EU Clinical Trials Register number 2008-002986-30. Dr. Karl-Anton Kreuzer, Dr. Lucien Noens, Dr. Thomas Pabst, Dr. Madhuri Vusirikala, Dr. Andrew Spencer, Dr. Anna Candoni, Dr. Jordi Sierra Gil, are principal investigators who contributed the patient data for the panobinostat monotherapy study CLB589B2213 with the EU Clinical Trials Register number: 2008-002983-32. Dr. Oliver Ottmann was the Senior Investigator for both trials.